Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559094 | 1.00 | SLC6A2 (0.49) | SLC6A2LGALS8LGALS3SLC5A1SLC5A2 | |
| SCHEMBL6559086 | 1.00 | SLC6A2 (0.49) | SLC6A2LGALS8LGALS3SLC5A1SLC5A2 | |
| SCHEMBL11981204 | 0.92 | SLC6A2 (0.45) | SLC6A2LGALS8LGALS3SLC5A1SLC5A2 | |
| SCHEMBL10436007 | 0.82 | SLC5A2 (0.43) | SLC5A1SLC5A2 | |
| SCHEMBL9029257 | 0.82 | SLC5A2 (0.43) | SLC5A1SLC5A2 | |
| SCHEMBL9029247 | 0.82 | SLC5A2 (0.43) | SLC5A1SLC5A2 | |
| SCHEMBL3156185 | 0.82 | SSTR5 (0.46) | SLC6A2LGALS8LGALS3TACR1NT5E | |
| SCHEMBL7902126 | 0.82 | SSTR5 (0.46) | SLC6A2LGALS8LGALS3TACR1NT5E | |
| SCHEMBL13381041 | 0.82 | SSTR5 (0.46) | SLC6A2LGALS8LGALS3TACR1NT5E | |
| SCHEMBL10767838 | 0.81 | SLC5A2 (0.45) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114970-B2 | Synthetic heparin monosaccharides | ALCHEMIA LIMITED (AU) | 2012-02-14 | — | — | US | disclosed |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2009-07-23 | — | — | US | disclosed |
| US-7541445-B2 | Synthetic heparin pentasaccharides | ALCHEMIA LIMITED (AU) | 2009-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | SLC6A2 4439/4885LGALS8 658/4885LGALS3 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.